Project Grant R21AI188909
- This $2,920,356 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to understand the role of norovirus capsid dynamics in enabling immune evasion. The project aims to leverage the highly tractable mouse norovirus system to elucidate the structural changes and host metabolite interactions that allow the virus to switch between antibody-recognized and...
- This federal Project Grant award of $188,208, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Program (CFDA 93.855), supports research to mechanistically investigate how retroviruses like HIV integrate their viral DNA into the chromatin of host cells. The proposed work will employ novel nucleosome reconstitution, biochemical assays, and cryo-electron microscopy to examine the preferred binding and integration...
- This federal Project Grant award of $603,338 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to understand how the HIV-1 virus mediates membrane fusion and entry into host cells. The research will use cryo-electron tomography and molecular dynamics simulations to investigate the structural interactions between the HIV-1 envelope glycoprotein, CD4 receptor, and co-receptors on cell...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $779,235 Project Grant under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855) to the University of California, Santa Cruz to study the mechanisms and consequences of cyclic di-GMP control of motility and biofilm formation in Vibrio cholerae. The research aims to address major gaps in understanding the interplay between V. cholerae's flagellum, pili, and cyclic di-GMP signaling in the...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $368,750 Project Grant to the Veterans Medical Research Foundation of San Diego through the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855). The project aims to determine the mechanisms by which the short isoform of the BST2 protein, which has broad antiviral activity, is antagonized by HIV-1 and HIV-2. This research seeks to understand how HIV evades this key cellular defense and the...
- This Project Grant award, valued at $102,444, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855). The goal of the project is to uncover structural insights into the N-terminal core of the SARS-CoV-2 nonstructural protein 1 (NSP1) and establish its specificity in regulating host gene expression, a process known as "host shutoff." This research aims to advance the...
- This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to develop novel multivalent mucosal vaccines for human noroviruses. The total funding is $798,173 with a project period from May 1, 2025 to April 30, 2030. The key products and services to be delivered include: 1) Developing multivalent, live-vectored mucosal norovirus vaccines using FDA-approved rotavirus (RotaTeq)...
- This Project Grant award, valued at $681,755.00 and issued by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research into the intracellular assembly, maturation, and trafficking of glycoprotein complexes from four rodent-infecting hantaviruses. The research aims to delineate the virus-host interactions required for the proper localization and function of these glycoprotein complexes, which...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $605,895 Project Grant under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855) to Rutgers, The State University to conduct research on cryogenic nanoimaging of adeno-associated virus (AAV) infection and packaging. The project aims to directly observe key steps in AAV infection and transduction using cryo-electron microscopy techniques, in order to determine the structural basis for barriers...
- The University of California, Santa Cruz received a $572,623 Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847) to study the interplay between early-life enteric virus infections and the development of oral tolerance. The project will examine how the goblet cell-tropic astrovirus virus impacts the ability of goblet cell-associated antigen passages (GAPS) to mediate tolerance to the dietary antigen, ovalbumin. Specifically, the research aims to...
This federal Project Grant award, in the amount of $416,005, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855). The purpose of the award is to define the molecular mechanisms of human astrovirus (HAstV) entry into human cells, with the goal of identifying targets for the development of vaccines and therapies. The research aims to use structural, biophysical, and virological approaches to (1) characterize the interactions between the HAstV capsid and the human neonatal Fc receptor (FcRn), which serves as a functional receptor for HAstV entry, and (2) elucidate the roles of FcRn and dipeptidyl-peptidase IV (DPP4) in HAstV attachment, internalization, capsid structural changes, and genome release. The award was made to the University of California, Santa Cruz, which has extensive experience in conducting federal research on infectious diseases, marine sciences, and other scientific domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $416.0k | 8/19/25 |